Literature DB >> 3812349

Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy.

F Delacrétaz, P M Schmidt, D Piguet, F Bachmann, J Costa.   

Abstract

Twenty-eight cases of myelodysplastic syndrome (MDS) were reviewed to evaluate whether the morphologic criteria proposed by the French-American-British (FAB) Cooperative Group for marrow smears could be applied to glycol methacrylate embedded trephine biopsies. Bone marrow biopsies and marrow smears were examined separately and then compared for the following parameters: percentage of blasts, dyserythropoiesis, ring sideroblasts, dysmegakaryopoiesis, dysgranulopoiesis, monocytes, cellularity, fibrosis, and "abnormal localization of immature precursors". The results of the histologic (biopsies) and cytologic (marrow smears) examinations were in good agreement in 24 of 28 cases. The authors' results suggest that the five MDS types proposed by the FAB group can be reliably distinguished on bone marrow biopsy with knowledge of the peripheral blood blast and monocyte counts. When the bone marrow aspiration is inadequate, the biopsy can establish diagnosis and type of MDS and rules out aplasia or tumor infiltration as possible alternative causes of cytopenia.

Entities:  

Mesh:

Year:  1987        PMID: 3812349     DOI: 10.1093/ajcp/87.2.180

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

Review 1.  Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia.

Authors:  D A Winfield; S V Polacarz
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

2.  Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.

Authors:  J Thiele; H Quitmann; S Wagner; R Fischer
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

3.  Hypocellular myelodysplastic syndromes: clinical and biological significance.

Authors:  Dragomir Marisavljevic; Vesna Cemerikic; Zoran Rolovic; Darinka Boskovic; Milica Colovic
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 4.  Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview.

Authors:  J Thiele; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  Histopathology of bone marrow in human immunodeficiency virus infection.

Authors:  F Delacrétaz; L Perey; P M Schmidt; J P Chave; J Costa
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

6.  Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance.

Authors:  M Werner; H Maschek; V Kaloutsi; H Choritz; A Georgii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

7.  Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.

Authors:  Lingyun Wu; Xiao Li; Jiying Su; Qi He; Xi Zhang; Chunkang Chang; Quan Pu
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-04       Impact factor: 4.553

8.  Dual colour FISH in paraffin wax embedded bone trephines for identification of numerical and structural chromosomal abnormalities in acute myeloid leukaemia and myelodysplasia.

Authors:  C L Le Maitre; R J Byers; J A Liu Yin; J A Hoyland; A J Freemont
Journal:  J Clin Pathol       Date:  2001-09       Impact factor: 3.411

9.  Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.

Authors:  H Maschek; V Kaloutsi; M Rodriguez-Kaiser; M Werner; H Choritz; K Mainzer; M Dietzfelbinger; A Georgii
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

Review 10.  Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).

Authors:  Peter Valent; Friedrich Wimazal; Ilse Schwarzinger; Wolfgang R Sperr; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.